The roles of manipulating hepatocyte TGR5 and TRIM21, as well as overexpressing BBOX1 and other therapeutic targets, in the progression from steatosis to MASH were explored in this study, considering both “therapeutic” and “prevention” approaches (Figure 7A). The gene discussed is GPBAR1; the disease is steatosis.